Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway

[Image: see text] Temozolomide (TMZ), as the first-line chemotherapeutic agent for the treatment of glioblastoma multiforme (GBM), often fails to improve the prognosis of GBM patients due to the quick development of resistance. The need for more effective management of GBM is urgent. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Jinbiao, Guo, Gaochao, Guo, Lianmei, Wang, Zengguang, Chen, Zhijuan, Nan, Yang, Cao, Yiyao, Li, Ruilong, Yang, Xuejun, Dong, Jun, Jin, Xun, Yang, Weidong, Huang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906592/
https://www.ncbi.nlm.nih.gov/pubmed/33644550
http://dx.doi.org/10.1021/acsomega.0c05399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906592/
https://www.ncbi.nlm.nih.gov/pubmed/33644550
http://dx.doi.org/10.1021/acsomega.0c05399

Ejemplares similares